Show simple item record

dc.contributor.authorParedes, Raisa
dc.contributor.authorVéliz, Fritner
dc.contributor.authorLucchetti, Aldo
dc.date.accessioned2021-05-03T13:57:35Z
dc.date.available2021-05-03T13:57:35Z
dc.date.issued2021-03-01
dc.identifier.issn08892229
dc.identifier.doi10.1089/aid.2020.0115
dc.identifier.urihttp://hdl.handle.net/10757/655814
dc.descriptionEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.en_US
dc.description.abstractIntroduction: In patients with HIV in antiretroviral treatment (ART) and virological failure to the first-line regimen, establishing a therapeutic regimen after having identified the M184V mutation, which confers ART resistance, represents a dilemma. Objective: To compare the virological response of the therapeutic regimens prescribed to patients with HIV who presented the M184V mutation in two national hospitals in Lima, Peru, during the years 2008 to 2019, and to determine the risk factors associated with poor virological response. Methods: A retrospective cohort study was developed based on the information of the HIV program participants with the M184V mutation. Results: A total of 175 participants were eligible for the study. The male sex predominated (75.4%), the current median age was 41 years [interquartile range (IQR) 35.84-47.47], and the time on ART was 89 months (IQR 57.7-124.53). The median initial viral load (VL) was 4.5 log10 copies/mL (IQR 3.97-5.09) and the time between genotyping and the change of therapy was 2 months (IQR 0-3.56). The most used antiretroviral regimen was protease inhibitor plus two nucleoside reverse transcriptase inhibitors (55.4%). With the protease inhibitor plus integrase inhibitor (PI + INI) ART, 69% less risk of poor virological response was obtained [p = .019 (confidence interval 95% 0.117-0.825)]. Conclusions: In patients with HIV and the M184V mutation, the PI + INI ART has shown a greater decrease in control VL and, thus, a good virological response. The risk factors associated with a poor virological response were the delay between genotyping and change of therapy, high levels of initial VL, and poor adherence among the participants.en_US
dc.formatapplication/pdfen_US
dc.language.isoengen_US
dc.publisherMary Ann Liebert Inc.en_US
dc.relation.urlhttps://www.liebertpub.com/doi/10.1089/AID.2020.0115?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmeden_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Academico - UPCes_PE
dc.subjectantiretroviral therapiesen_US
dc.subjectHIVen_US
dc.subjectHIV geneticsen_US
dc.subjectCohort analysisen_US
dc.subjectControlled studyen_US
dc.subjectGenotypeen_US
dc.subjectHuman immunodeficiency virus infected patienten_US
dc.subjectMajor clinical studyen_US
dc.subjectMulticenter studyen_US
dc.titleComparison of the Virological Response According to the Antiretroviral Regimens in Peruvian HIV Patients Who Presented the M184V Mutation in Two National Hospitals during the Years 2008 to 2019en_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.identifier.eissn19318405
dc.identifier.journalAIDS Research and Human Retrovirusesen_US
dc.description.peerreviewRevisión por pareses_PE
dc.identifier.eid2-s2.0-85102244384
dc.identifier.scopusidSCOPUS_ID:85102244384
dc.source.journaltitleAIDS Research and Human Retroviruses
dc.source.volume37
dc.source.issue3
dc.source.beginpage196
dc.source.endpage203
dc.identifier.isni0000 0001 2196 144X


This item appears in the following Collection(s)

Show simple item record